Role of holmium laser enucleation of the prostate for the diagnosis of prostate cancer in patients with gray-zone PSA levels
Other Titles
회색 지대의 전립선 특이 항원 값이 측정되는 환자에서 전립선암의 진단을 위한 홀륨 레이저를 이용한 전립선 절제술의 역할
Authors
김기홍
Department
Dept. of Urology (비뇨의학교실)
Issue Date
2016
Description
의과대학/석사
Abstract
Purpose
Even though the safety of the treatment for prostate cancer diagnosed by HoLEP has been reported, the diagnostic value of HoLEP for prostate cancer detection has not been confirmed. Therefore, we investigated the diagnostic potential of HoLEP for detecting prostate cancer.
Patients and Method
Between December 2008 and October 2014, 359 patients (median age, 70.9 years; range, 66.2-74.8) were treated simultaneously with HoLEP and transrectal prostate needle biopsy (TPNB). Of these, 199 patients with a normal digital rectal examination and serum PSA concentration between 3.5 and 10.0 ng/ml were included in the study. Univariate and multivariate logistic regression analyses were performed to identify the predictive factor for prostate cancer detected by HoLEP.
Results
Median PSA, prostate volume and PSA density were 4.97 ng/ml (range, 4.20-6.70), 57.40 gm (range, 43.67-77.80) and 0.09 ng/ml2 (range, 0.07-0.12), respectively. Clinically significant prostate cancer (Gleason score ≥6) was detected in 46 cases (23.1%). Of these, 26 (56.5%) were detected by HoLEP pathology, 11 (23.9%) by TPNB pathology, and 9 (19.6%) by both. Univariate and multivariate logistic regression analyses were performed in 179 patients, including benign prostatic hyperplasia patients (N=153, 76.9%) and patients with cancer detected by HoLEP pathology. PSA density was identified as an independent predictor of prostate cancer detected by HoLEP in gray-zone PSA.
Conclusion
HoLEP is a viable modality for detecting prostate cancer in selected cases. PSA density was an independent predictor of prostate cancer detected by HoLEP in gray-zone PSA.